It has long been known that the synaptic vesicles of certain glutamatergic terminals, as well as some inhibitory terminals, are richly supplied with zinc ions, yet the functional role of this pool of zinc in synaptic transmission has remained elusive. In this issue of Neuron, Hirzel et al. provide direct in vivo evidence that endogenous zinc is required for proper functioning of neuronal circuitry in the brainstem and spinal cord. They show that knockin mice carrying a point mutation which eliminates zinc potentiation of a1-containing glycine receptors develop severe sensorimotor deficits characteristic of impaired glycinergic neurotransmission.
Zinc is an indispensable element in the molecular economy of all cells. While most zinc ions are trapped within proteins, as structural or catalytic cofactors, in the brain, there is a pool of zinc that is less tightly bound and that can be revealed by histochemical techniques, such as the Timm's stain. The distribution of this potentially mobilizable zinc is remarkable for two reasons: first, it is mainly restricted to higher brain regions (viz. neocortex, hippocampus, striatum, and amygdala); second, at the ultrastructural level, histochemically reactive zinc is localized almost exclusively within synaptic vesicles of a subset of glutamatergic axon terminals, where it is accumulated by the vesicular zinc transporter ZnT3 (Frederickson et al., 2005) . However, there are notable exceptions to these rules since recently some staining of ''chelatable'' zinc has also been found in certain inhibitory axon terminals of the cerebellum and spinal cord (Danscher and Stoltenberg, 2005) .
Most of the key players in fast synaptic transmission are highly sensitive to extracellular zinc (Smart et al., 2004; Frederickson et al., 2005) . This is the case for both the neurotransmitter receptors and transporters of excitatory and inhibitory transmission and, depending on the nature of the target, zinc may either boost or depress the synaptic response. Zinc is a potent inhibitor of NMDA and GABA A receptors as well as glutamate and GABA transporters. In contrast, at glycine receptors, zinc displays a biphasic effect, potentiating at submicromolar concentrations and inhibiting at submillimolar concentrations.
The abundance of potential synaptic targets and the location of zinc in synaptic vesicles all seem to point to a role for zinc as a modulator of synaptic transmission (Vogt et al., 2000) . However, despite clear indications that endogenous zinc is involved in excitotoxicity under pathological conditions (Choi and Koh, 1998) , there has been no clear demonstration of a role for zinc in synaptic transmission under physiological conditions. Moreover, two recent findings have cast some doubt upon the physiological relevance of zinc modulation. Knocking out the ZnT3 gene leads to the total disappearance of histochemical reactive zinc, yet results in no marked phenotype other than a moderate increase in susceptibility to epileptic seizures (Cole et al., 2000) . Furthermore, whether zinc is indeed elevated in the synaptic cleft during neuronal activity has been challenged by experiments using zinc-sensitive fluorescent indicators, which suggest that zinc may after exocytosis stick to the presynaptic membrane and not diffuse freely in the cleft (Kay, 2006) .
In this context, the paper by Hirzel et al. (2006) (this issue of Neuron), will certainly revive the flagging hopes of zincologists. This work provides a clear demonstration that interfering with zinc modulation of a synaptic pathway leads to a significant alteration in the phenotype of the animal. The authors used an original approach that circumvents most of the bugaboos encountered in previous attempts to pin down the role of zinc. Rather than modifying zinc levels with zinc chelators or genetic manipulations, which necessarily produce pleiotropic effects, Hirzel et al. (2006) chose to modify a specific synaptic zinc target, the glycine receptor, which mediates synaptic inhibition in the brainstem and spinal cord. Given the strong association of zinc with glutamatergic terminals, picking this particular target was risky, but Hirzel et al. (2006) clearly show that it paid off. The authors produced a knockin (KI) mouse by introducing in the gene coding for the murine a1 glycine receptor subunit a point mutation (D80A) known from previous studies on recombinant receptors to suppress high-affinity zinc potentiation. Around P12, when the adult a1 GlyR subunit replaces the neonatal a2 subunit, KI mice develop both motor and sensory deficits typical of impaired glycinergic transmission: inducible tremor, delayed righting reflex, abnormal gait, increase in electroretinogram b-wave amplitude, and an enhanced acoustic startle response. This behavior is similar to a genetic disorder in human infants termed hyperekplexia (startle disease), which is characterized by an exaggerated startle reflex, with ensuing stiffness and marked brainstem reflexes.
At the cellular level, the authors carefully verified that the mutation selectively eliminated the high-affinity zinc potentiation of glycine receptors without affecting their glycine sensitivity, expression level, and synaptic targeting. They further compared inhibitory transmission in wild-type (WT) and KI animals by recording in brain stem slices spontaneous IPSCs from hypoglossal motoneurons. The striking observation was that at P14-P16, when a1 GlyR subunit dominates, both the IPSC amplitude and decay are reduced in KI compared to WT animals. These results clearly indicate that in WT animals, endogenous zinc effectively binds to and potentiates synaptic glycine receptors by increasing receptor sensitivity to the agonist. Undoubtedly this work is important, since it directly demonstrates that zinc acts as an endogenous modulator of synaptic transmission.
Exciting as these results are, there are of course many questions that remain, e.g., how much zinc is seen by the receptors. Does zinc act in a tonic or phasic fashion? Where does it come from? Surprisingly, Hirzel et al. (2006) found that application of exogenous zinc at low mM concentrations to WT slices did not increase the amplitude of glycinergic IPSCs, suggesting that in slices the zinc potentiating site on GlyRs is persistently saturated. Consistent with this interpretation, the authors found that application of the chelator tricine depressed the IPSCs in WT but not KI animals. However, the authors' conclusion that the levels of ambient zinc are in the mM range is more questionable. This relies on the estimated affinity of the zinc potentiating site on GlyRs. Using buffered zinc solutions with controlled free zinc concentrations, other groups have measured zinc affinities of native and cloned glycine receptors more than one order of magnitude higher than that reported by Hirzel et al. (Suwa et al., 2001; Miller et al., 2005) . Therefore, synaptic zinc levels in the 10-100 nM range may be sufficient to prevent potentiation by exogenously applied zinc.
There are two ways in which we can imagine zinc modulating synaptic transmission (see Figure 1) . First, phasically, where synaptic zinc diffuses freely into the synaptic cleft after exocytosis and then binds to postor presynaptic receptors and transporters. Zinc modulation would then wane rapidly as the zinc diffuses away and is transported into cells. Second, tonically, where zinc is bound to proteins within the synaptic vesicle and is externalized on exocytosis but not much diffuses into the cleft. Under this scenario, a few zinc ions could be supplied to an extracellular layer of zinc, termed the ''veneer' ' (Kay, 2006) , where the metal stays associated with proteins on the pre-and postsynaptic membranes, including the neurotransmitter receptors. The degree of tonic zinc modulation would be determined by the number of zinc ions in the veneer, which accumulate slowly and progressively with synaptic activity and declines as zinc is removed from the veneer. High enough tonic zinc would explain the absence of effect seen by Hirzel et al. (2006) upon application of exogenous zinc. However, these results are also compatible with a phasic mechanism, assuming that during normal synaptic activity zinc transiently reaches concentrations high enough to saturate the GlyR zinc binding site. Thus, whether the modulation occurs via the phasic rise of zinc or through regulation of the tonic level of extracellular zinc remains wide open; clearly, more experiments are needed. This question applies also to two other major neurotransmitter receptors involved in fast neurotransmission, NMDA and GABA A receptors, since both receptor families harbor zinc binding sites of high sensitivity (nM affinity; Paoletti et al., 1997; Hosie et al., 2003) .
What is the source of zinc at a glycinergic synapse? One possibility could be that glycinergic presynaptic vesicles accumulate zinc, as do glutamatergic and some GABAergic terminals. Looking for ZnT3 expression in glycinergic neurons and analyzing zinc modulation of glycinergic transmission in ZnT3 2/2 animals should help clarify this point, although the fact that ZnT3 KOs do not show hyperekplexia makes it unlikely that ZnT3 loads vesicles associated with GlyR modulation. There is certainly no shortage of potential zinc transporters that could do the job, as numerous genes have been identified that code for proteins transporting zinc into intracellular compartments (Palmiter and Huang, 2004) . Spillover of zinc from neighboring synapses, likely glutamatergic, may provide an alternative source of zinc (Kodirov et al., 2006 , and see Figure 1 ).
The work of Hirzel et al. (2006) puts a nice dent in the zinc armor, which held firm for more than 50 years, with their demonstration that this ion acts as a physiological neuromodulator of glycinergic transmission. Oddly enough, zinc makes its debut as a synaptic neuromodulator not at the zinc-enriched glutamatergic synapses of the forebrain where one would have expected, but rather at glycinergic synapses in the hindbrain. We have little doubt that this initial success by inhibitory ''outsiders'' will trigger excitement in the glutamatergic transmission field, where the paradox of the coexistence of an activator (glutamate) and an inhibitor (zinc) remains unsolved. Maps, Codes, and Sequence Elements: Can We Predict the Protein Output from an Alternatively Spliced Locus?
Alternative splicing choices are governed by splicing regulatory protein interactions with splicing silencer and enhancer elements present in the pre-mRNA. However, the prediction of these choices from genomic sequence is difficult, in part because the regulators can act as either enhancers or silencers. A recent study describes how for a particular neuronal splicing regulatory protein, Nova, the location of its binding sites is highly predictive of the protein's effect on an exon's splicing.
In eukaryotic cells, the formation of a mature mRNA requires the removal of introns from the precursor mRNA and splicing of its exons. This is a key step in determining the protein output from a gene. Alternative splicing allows joining of exons in different patterns, enabling a single gene to produce multiple protein isoforms (Black, 2003) . This form of regulation is particularly common in the mammalian nervous system where a large percentage (40%-60%) of neuronal pre-mRNAs undergo alternative splicing (Yeo et al., 2004) . Many of these splicing events produce proteins important for neuronal development (e.g. neurexins, EphA7) and mature neuronal function (e.g. NMDA receptor 1, CaV2), and changes in the splicing of their pre-mRNAs result in multiple functional variants (Lipscombe, 2005) . A long-term goal of genomic research is the prediction of the protein products of a gene under different cellular conditions. However, the frequency with which gene transcripts show alternative splicing in the nervous system and the large number of potential products from some of these genes make this prediction extremely difficult. The information that determines an alternative splicing pattern is usually encoded within the sequence of a regulated exon and its flanking introns in the form of intronic or exonic splicing silencer elements (ISS or ESS) and intronic or exonic splicing enhancer elements (ISE or ESE) . Enhancer elements promote the inclusion of an exon, and silencers promote its skipping or exclusion from the final mRNA. Many of these elements are bound by known RNA-binding proteins (RBPs), such as the SR proteins and members of the hnRNP group of proteins (Black, 2003) . Many more elements have been identified, but their protein mediators are unknown. Most alternative exons are controlled by multiple splicing enhancer and silencer elements. Moreover, many elements are not strict silencers or enhancers, rather the position of an element relative to an alternative exon can determine whether it acts positively or negatively (Hui et al., 2005) . We need to know much more about the rules that determine the positive or negative activity of these regulatory elements. What is the code for exon use? What are the mechanisms by which these elements act on the splicing apparatus? A recent paper in Nature shows for one splicing regulator that such a code exists and can successfully predict the regulatory properties of the exon targets for this protein (Ule et al., 2006) . Moreover, this paper and recent work from others have started to identify the specific steps in spliceosome assembly affected by a regulatory protein.
Genomic analyses of alternative splicing indicate that the brain has the highest frequency of alternative splicing (Sugnet et al., 2006; Yeo et al., 2004) . The neuronspecific inclusion or skipping of alternative exons is primarily achieved by tissue-specific expression of particular RBPs (Matlin et al., 2005) . Over a dozen neuronspecific RBPs have been identified, including the Hu family, members of the CELF family, neural PTB, the Fox protein family, and Nova-the subject of the Nature paper (McKee et al., 2005; Ule et al., 2006) . These regulators affect a wide range of target gene transcripts, encoding proteins involved in cytoskeletal rearrangement, vesicular transport, cell adhesion, signal transduction pathways, and synaptic activity (Lipscombe, 2005) . In earlier work, the Darnell lab identified Nova protein as a YCAY element binding factor. They went on to use a variety of biochemical, genomic, and genetic approaches to identify a large number of exons in genes affecting synaptic function whose splicing was affected by Nova (Ule et al., 2006 , and references therein).
The known Nova-regulated exons showed a variety of dependencies, some enhanced by the protein and others repressed. In the present study, the authors carried out statistical analyses of the positions of YCAY clusters relative to the known Nova target exons (Ule et al., 2006) . They noted the positions of these clusters relative to the target exon and created a general map relating the frequency of YCAY clusters surrounding Nova-regulated exons. These clusters fall into relatively few defined positions upstream, downstream, or within the exon (Figure 1) . Interestingly, certain positions strongly correlate with splicing enhancement by Nova, while other positions correlate with Nova acting to repress splicing. The authors tested the predictive value of the map by searching a genomic database for additional YCAY cluster-containing exons that had not been previously identified as Nova targets. The splicing of these exons was compared in wild-type and Nova knockout mice. They found that the positions of Novadependent enhancers and silencers indicated by the map were strongly predictive of the changes observed between the presence and absence of Nova. This both validated the value of the Nova RNA map and identified a new set of Nova target exons.
